샘플 요청 목록

 카트 문의
시장보고서
상품코드
2148440

불안 장애 치료 시장

Anxiety Disorder Treatment
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 399 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,938,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,083,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,815,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 불안 장애 치료 시장은 2032년까지 191억 달러에 달할 것으로 전망

2025년 155억 달러로 추정되는 세계 불안 장애 치료 시장은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 3.0%로 확대되어 2032년까지 191억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석 대상으로 다루고 있는 부문 중 하나인 ‘항우울제’는 연평균 성장률(CAGR) 2.2%를 기록하며, 분석 기간 종료 시점까지 53억 달러에 달할 것으로 예측됩니다. ‘항불안제’ 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 3.8%를 나타낼 것으로 추정됩니다.

미국 시장은 42억 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 5.1%를 나타낼 것으로 예측됩니다.

미국의 불안 장애 치료 시장은 2025년에 42억 달러로 추산됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 5.1%를 기록하며 2032년까지 시장 규모가 37억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 1.4% 및 2.3%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 1.9%를 나타낼 것으로 예측됩니다.

불안 장애 치료 - 주요 동향 및 촉진요인

불안 장애 치료에는 일반화된 불안 장애(GAD), 공황 장애, 사회 불안 장애, 특정 공포증 등 다양한 불안 장애 증상을 완화하기 위해 고안된 광범위한 치료 접근법과 약물 요법이 포함됩니다. 이러한 치료는 일상생활에 중대한 영향을 미치는 과도한 공포, 불안 및 그에 따른 행동 변화를 완화하는 것을 목표로 합니다. 심리치료, 특히 인지행동치료(CBT)는 불안 장애의 1차 치료법으로 간주됩니다. CBT는 환자가 부정적인 사고 패턴과 행동을 인식하고 수정할 수 있도록 돕는 동시에, 불안을 관리하기 위한 대처법을 지도합니다. 그 밖의 치료 접근법으로는 통제된 환경에서 환자를 공포를 느끼는 상황에 단계적으로 노출시키는 ‘노출 요법’, 환자가 불안을 수용하면서 행동 변화를 도모하도록 유도하는 ‘수용 및 헌신 요법(ACT)’ 등이 있습니다.

약물 치료도 불안 장애 치료의 중요한 축 중 하나이며, 대부분의 경우 심리 치료와 병행됩니다. 선택적 세로토닌 재흡수 억제제(SSRI) 및 세로토닌·노르에피네프린 재흡수 억제제(SNRI)는 그 유효성과 비교적 양호한 부작용 프로파일로 인해 일반적으로 1차 선택 약물로 처방됩니다. 벤조디아제핀계 약물은 단기적인 증상 완화에는 효과적이지만, 의존성이나 금단 증상의 위험이 있으므로 일반적으로 신중하게 처방됩니다. 또한, 불안의 신체적 증상 관리에 일반적으로 사용되는 베타 차단제나, 치료 저항성 사례에 대한 비정형 항정신병제 등 다른 유형의 약물도 활용되고 있습니다. 약물 요법의 최근 동향은 환자에게 더 나은 치료 결과를 가져다주기 위해, 부작용이 적고 글루타메이트계나 엔도카나비노이드계를 표적으로 하는 새로운 작용기전을 가진 약물의 개발에 초점을 맞추었습니다.

불안 장애 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 세계적으로 불안 장애의 유병률이 증가하고 있는 것이 큰 요인이며, 인식 제고와 진단 증가가 효과적인 치료법에 대한 수요 증가에 기여하고 있습니다. 둘째, 디지털 헬스 분야의 기술 발전으로 인해 원격 치료나 모바일 헬스 앱을 통한 정신 건강 관리 접근성이 확대되고 있으며, 특히 외진 지역에서도 치료를 더 쉽게 이용할 수 있게 되었습니다. 셋째, 정신 건강에 대한 편견이 점차 사라지면서 더 많은 사람들이 치료를 찾고 있습니다. 또한, 약물 요법에 대한 지속적인 연구 개발을 통해 유효성과 안전성이 향상된 혁신적인 치료 옵션이 등장하고 있습니다. 아울러, 정신 건강 서비스가 1차 진료 현장에 통합됨에 따라 불안 장애의 조기 발견 및 관리가 개선되고 있습니다. 마지막으로, 정부의 지원 정책과 의료비 증가는 정신건강 치료의 개발과 접근성을 뒷받침하며 시장 성장을 더욱 가속화하고 있습니다. 이러한 요인들은 종합적으로 불안 장애 치료 시장의 역동적이고 끊임없이 진화하는 특성을 부각시키는 동시에, 세계 정신 건강 성과 향상에 있어 해당 시장이 수행하는 매우 중요한 역할을 강조하고 있습니다.

부문:

약제 유형(항우울제, 항불안제, 항경련제, 노르아드레날린 작용제, 비정형 항정신병제), 적응증(우울증, 불안 장애), 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)

주요 기업

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Noven Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Shionogi &Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.

해당 분야의 전문가들의 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 제공합니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합합니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 관여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.28

Global Anxiety Disorder Treatment Market to Reach US$19.1 Billion by 2032

The global market for Anxiety Disorder Treatment estimated at US$15.5 Billion in the year 2025, is expected to reach US$19.1 Billion by 2032, growing at a CAGR of 3.0% over the analysis period 2025-2032. Antidepressants Drug Type, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Anxiolytics Drug Type segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.2 Billion While China is Forecast to Grow at 5.1% CAGR

The Anxiety Disorder Treatment market in the U.S. is estimated at US$4.2 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2032 trailing a CAGR of 5.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Anxiety Disorder Treatment - Key Trends and Drivers

Anxiety disorder treatment encompasses a range of therapeutic approaches and medications designed to alleviate the symptoms of various anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias. These treatments aim to reduce excessive fear, worry, and associated behavioral changes that significantly impact daily functioning. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is considered a frontline treatment for anxiety disorders. CBT helps patients identify and modify negative thought patterns and behaviors, teaching coping strategies to manage anxiety. Other therapeutic approaches include exposure therapy, which gradually exposes patients to feared situations in a controlled manner, and acceptance and commitment therapy (ACT), which encourages patients to accept their anxiety while committing to behavior changes.

Medications are another cornerstone of anxiety disorder treatment, often used in conjunction with psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed first-line medications due to their efficacy and relatively favorable side effect profiles. Benzodiazepines, while effective for short-term relief, are generally prescribed with caution due to the risk of dependency and withdrawal issues. Additionally, other classes of medications such as beta-blockers, which are typically used to manage physical symptoms of anxiety, and atypical antipsychotics for treatment-resistant cases, are also utilized. Recent advancements in pharmacotherapy are focusing on developing medications with fewer side effects and novel mechanisms of action, such as targeting the glutamate system or the endocannabinoid system, to provide better outcomes for patients.

The growth in the anxiety disorder treatment market is driven by several factors. Firstly, the rising prevalence of anxiety disorders globally is a significant driver, with increasing awareness and diagnosis contributing to higher demand for effective treatments. Secondly, technological advancements in digital health are expanding access to mental health care through teletherapy and mobile health applications, making treatments more accessible, especially in remote areas. Thirdly, the stigma around mental health is gradually diminishing, encouraging more individuals to seek treatment. Moreover, continuous research and development in pharmacotherapy are leading to innovative treatment options with improved efficacy and safety profiles. Additionally, the integration of mental health services into primary care settings is improving the identification and management of anxiety disorders. Lastly, favorable government policies and increasing healthcare expenditure are supporting the development and accessibility of mental health treatments, further propelling market growth. These factors collectively highlight the dynamic and evolving nature of the anxiety disorder treatment market, emphasizing its critical role in improving mental health outcomes globally.

SCOPE OF STUDY:

The report analyzes the Anxiety Disorder Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type, Atypical Antipsychotics Drug Type); Indication (Depression Indication, Anxiety Indication); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Noven Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Shionogi & Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Anxiety Disorder Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 63 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anxiety Disorders Throws the Spotlight on Need for Effective Treatments
    • Adoption of Digital Therapeutics in Anxiety Management Spurs Market Expansion
    • Integration of Mental Health Services into Primary Care Strengthens Business Case for Comprehensive Care Models
    • Continuous Research and Development in Pharmacotherapy Generates New Treatment Options
    • Innovations in Psychotherapy Techniques Improves Patient Outcomes
    • Rising Utilization of Mobile Health Applications Drives Demand for Accessible Treatment Options
    • Development of Medications with Novel Mechanisms of Action Expands Therapeutic Landscape
    • Growing Popularity of Acceptance and Commitment Therapy (ACT) Generates Interest in Alternative Therapies
    • Advances in Understanding of Neurobiological Mechanisms Propel Growth in Personalized Medicine
    • Growing Investment in Mental Health Infrastructure Expands Addressable Market Opportunity
    • Rising Awareness of Comorbid Conditions Drives Comprehensive Treatment Strategies
    • Expansion of Insurance Coverage for Mental Health Services Strengthens Business Case for Providers
    • Growth in Corporate Mental Health Programs Generates Demand for Anxiety Disorder Treatments
    • Advances in Genetic Research Propel Growth in Targeted Anxiety Therapies
    • Increasing Consumer Preference for Non-Pharmacological Treatments Drives Adoption of Alternative Therapies
    • Challenges in Medication Side Effects Create Opportunities for New Drug Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anxiety Disorder Treatment Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Antidepressants Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Antidepressants Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Anxiolytics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Anxiolytics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Anxiolytics Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Anticonvulsants Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Anticonvulsants Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Noradrenergic Agents Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Noradrenergic Agents Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Noradrenergic Agents Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Atypical Antipsychotics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Atypical Antipsychotics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Atypical Antipsychotics Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Depression Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Depression Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Depression Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Anxiety Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Anxiety Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Anxiety Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 38: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 41: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • JAPAN
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • CHINA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 65: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 68: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • EUROPE
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • FRANCE
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 86: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 89: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • GERMANY
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 113: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 116: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Spain Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: Spain 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Spain Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Spain 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Spain Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Spain 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Russia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Russia 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Russia Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Russia 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Russia Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Russia 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of Europe 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of Europe 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Australia Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Australia 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Australia Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Australia 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Australia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Australia 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • INDIA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: India Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: India 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 170: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: India Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: India 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
    • TABLE 173: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: India Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: India 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: South Korea Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: South Korea 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: South Korea Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: South Korea 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: South Korea Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: South Korea 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Latin America 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Latin America Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Latin America 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Argentina Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Argentina 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Argentina Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Argentina 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Argentina Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Argentina 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Brazil Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Brazil 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Brazil Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Brazil 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Brazil Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Brazil 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Mexico Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Mexico 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Mexico Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Mexico 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Mexico Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Mexico 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Latin America 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Latin America 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Latin America 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Middle East 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Middle East Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Middle East 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Iran Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Iran 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Iran Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Iran 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Iran Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Iran 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Israel Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Israel 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Israel Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Israel 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Israel Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Israel 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Saudi Arabia 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Saudi Arabia 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Saudi Arabia 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: UAE Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: UAE 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: UAE Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: UAE 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: UAE Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: UAE 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Rest of Middle East 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Rest of Middle East 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Rest of Middle East 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032
  • AFRICA
    • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Africa Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Africa 13-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Africa Historic Review for Anxiety Disorder Treatment by Drug Type - Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Africa 13-Year Perspective for Anxiety Disorder Treatment by Drug Type - Percentage Breakdown of Value Sales for Antidepressants Drug Type, Anxiolytics Drug Type, Anticonvulsants Drug Type, Noradrenergic Agents Drug Type and Atypical Antipsychotics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Africa Historic Review for Anxiety Disorder Treatment by Indication - Depression Indication and Anxiety Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Africa 13-Year Perspective for Anxiety Disorder Treatment by Indication - Percentage Breakdown of Value Sales for Depression Indication and Anxiety Indication for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기